Skip to main content
. 2021 Oct 21;7(1):108–116. doi: 10.1016/j.ekir.2021.10.012

Figure 2.

Figure 2

Kidney survival rate in male patients with XLAS. The solid line represents splicing variants detected in this study, and the dotted, dashed, and dot-dashed lines represent missense variants, intronic splicing variants, and nonsense variants reported in our previous study, respectively. The Kaplan–Meier kidney survival analysis results revealed that the median age for developing end-stage kidney disease was significantly lower for patients with splicing variants in our present study compared with those with missense variants in our previous study (27 years of age, 95% CI: 22–29 vs. 40 years of age, 95% CI: 35–45; Wilcoxon: P < 0.01). Nevertheless, there was no significant difference in the median age for developing end-stage kidney disease between patients with splicing variants in this study and those in our previous study with intronic splicing variants (27 years of age, 95% CI: 22–29 vs. 28 years of age, 95% CI: 24–35; P = 0.72) or nonsense variants (27 years of age, 95% CI: 22–29 vs. 18 years of age, 95% CI: 16–27; P = 0.09).